Praxis Precision Medicines Submits Two NDAs for Ulixacaltamide and Relutrigine, Reports Q4/FY25 Results, and Extends Cash Runway into 2028
PRAX has more than doubled off its 52-week low of $26.7.
Summary
Praxis Precision Medicines announced the submission of two New Drug Applications (NDAs) to the FDA for ulixacaltamide and relutrigine, reported Q4 and full-year 2025 financial results, and confirmed a cash runway extending into 2028.
Key Events · Product Development and Regulatory · PRAX
-
Two NDAs Submitted to FDA
Praxis submitted New Drug Applications (NDAs) for ulixacaltamide in essential tremor (ET) and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), marking a critical step towards commercialization.
-
Extended Cash Runway
The company reported $926.1 million in cash and investments as of December 31, 2025, which, combined with $621.2 million from the January 2026 public offering, is expected to fund operations into 2028.
-
Positive Pipeline Progress
Pre-launch activities for ulixacaltamide and relutrigine are accelerating, and topline results for vormatrigine (FOS) and elsunersen (SCN2A DEE) are anticipated in the first half of 2026.
-
Full-Year 2025 Financials
Praxis reported a net loss of $303.3 million for the full year 2025, with research and development expenses increasing to $267.1 million, reflecting significant investment in its pipeline.
Analysis · PRAX · Life Sciences
This 8-K filing signals a significant advancement for Praxis Precision Medicines as it transitions towards becoming a commercial-stage biopharmaceutical company. The submission of two New Drug Applications (NDAs) for ulixacaltamide in essential tremor and relutrigine in DEEs represents a major de-risking event for its pipeline, with pre-launch activities already underway. The robust cash position, bolstered by the recent public offering, provides a substantial runway into 2028, alleviating near-term financing concerns and supporting ongoing R&D and commercialization efforts. Upcoming clinical readouts for vormatrigine and elsunersen in the first half of 2026 will be key catalysts to watch, potentially adding to the company's late-stage pipeline.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 36.7% of the 1012 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRAX was trading at $328.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $26.70 to $335.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.